NO920494L - Terapeutiske, heterosykliske forbindelser - Google Patents

Terapeutiske, heterosykliske forbindelser

Info

Publication number
NO920494L
NO920494L NO92920494A NO920494A NO920494L NO 920494 L NO920494 L NO 920494L NO 92920494 A NO92920494 A NO 92920494A NO 920494 A NO920494 A NO 920494A NO 920494 L NO920494 L NO 920494L
Authority
NO
Norway
Prior art keywords
formula
heterocyclic
relations
therapeutic
alkyl
Prior art date
Application number
NO92920494A
Other languages
English (en)
Other versions
NO920494D0 (no
NO300634B1 (no
Inventor
Alan Duncan Robertson
Alan Peter Hill
Robert Charles Glen
Graeme Richard Martin
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26297174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO920494(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909012672A external-priority patent/GB9012672D0/en
Priority claimed from GB919102182A external-priority patent/GB9102182D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of NO920494D0 publication Critical patent/NO920494D0/no
Publication of NO920494L publication Critical patent/NO920494L/no
Publication of NO300634B1 publication Critical patent/NO300634B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
NO920494A 1990-06-07 1992-02-06 Analogifremgangsmåte for fremstilling av terapeutisk aktive heterocykliske forbindelser NO300634B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909012672A GB9012672D0 (en) 1990-06-07 1990-06-07 Therapeutic heterocyclic compounds
GB919102182A GB9102182D0 (en) 1991-02-01 1991-02-01 Therapeutic heterocyclic compounds
PCT/GB1991/000908 WO1991018897A1 (en) 1990-06-07 1991-06-06 Therapeutic heterocyclic compounds

Publications (3)

Publication Number Publication Date
NO920494D0 NO920494D0 (no) 1992-02-06
NO920494L true NO920494L (no) 1992-03-30
NO300634B1 NO300634B1 (no) 1997-06-30

Family

ID=26297174

Family Applications (2)

Application Number Title Priority Date Filing Date
NO920494A NO300634B1 (no) 1990-06-07 1992-02-06 Analogifremgangsmåte for fremstilling av terapeutisk aktive heterocykliske forbindelser
NO1998005C NO1998005I1 (no) 1990-06-07 1998-01-21 Zolmitriptan

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1998005C NO1998005I1 (no) 1990-06-07 1998-01-21 Zolmitriptan

Country Status (37)

Country Link
US (3) US5399574A (no)
EP (2) EP0636623B1 (no)
JP (1) JP2738461B2 (no)
KR (1) KR100215627B1 (no)
AT (2) ATE204275T1 (no)
AU (1) AU646871B2 (no)
CA (2) CA2282890C (no)
CZ (1) CZ288351B6 (no)
DE (3) DE19775091I2 (no)
DK (1) DK0486666T3 (no)
EG (1) EG19650A (no)
ES (1) ES2104708T3 (no)
FI (3) FI105686B (no)
GR (1) GR3024828T3 (no)
HK (1) HK1000534A1 (no)
HR (1) HRP940524B1 (no)
HU (2) HU219974B (no)
IE (1) IE911931A1 (no)
IL (3) IL114690A (no)
LT (1) LT3264B (no)
LU (1) LU90205I2 (no)
LV (1) LV10274B (no)
MC (1) MC2210A1 (no)
MX (1) MX9203421A (no)
MY (1) MY110226A (no)
NL (1) NL980001I2 (no)
NO (2) NO300634B1 (no)
NZ (1) NZ238424A (no)
PL (1) PL166214B1 (no)
PT (1) PT97888B (no)
RU (1) RU2160736C2 (no)
SA (1) SA05260104B1 (no)
SI (2) SI21560B (no)
SK (1) SK281621B6 (no)
UA (1) UA37178C2 (no)
WO (1) WO1991018897A1 (no)
YU (1) YU48855B (no)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
TW263508B (no) * 1991-02-12 1995-11-21 Pfizer
BR9206810A (pt) * 1991-11-25 1995-10-31 Pfizer Derivados de indol
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
TW288010B (no) * 1992-03-05 1996-10-11 Pfizer
CA2129146A1 (en) * 1992-03-13 1993-09-16 Victor Giulio Matassa Imidazole, triazole and tetrazole derivatives
GB9207396D0 (en) * 1992-04-03 1992-05-13 Merck Sharp & Dohme Therapeutic agents
AU670579B2 (en) * 1992-04-07 1996-07-25 Pfizer Inc. Indole derivatives as 5-HT1 agonists
US6380233B1 (en) 1992-04-07 2002-04-30 Pfizer Inc Indole derivatives as 5-HT1 agonists
NZ251047A (en) * 1992-04-10 1996-09-25 Pfizer Acylaminoindole derivatives and medicaments
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9208463D0 (en) * 1992-04-16 1992-06-03 Merck Sharp & Dohme Therapeutic agents
GB9209882D0 (en) * 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
CA2138649A1 (en) * 1992-07-24 1994-02-03 Raymond Baker Imidazole, triazole and tetrazole derivatives
GB9216009D0 (en) * 1992-07-28 1992-09-09 Almirall Lab New indol derivatives
IL106445A (en) * 1992-07-30 1998-01-04 Merck Sharp & Dohme History of 1,2,4-Trans-Triazole 4-Transform, Preparation and Pharmaceutical Preparations Containing Them
ES2056025B1 (es) * 1992-10-08 1995-05-01 Almirall Lab Nuevos derivados de indol.
TW251284B (no) * 1992-11-02 1995-07-11 Pfizer
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
ES2070087B1 (es) * 1993-08-13 1996-02-16 Pfizer Derivados de indol
DE69413240T2 (de) * 1993-08-31 1999-02-04 Pfizer 5-arylindolderivate
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
US6423731B2 (en) * 1994-01-06 2002-07-23 Zeneca Limited Indole derivatives as prodrugs of 5-HT1-like receptor agonists
GB9401436D0 (en) * 1994-01-26 1994-03-23 Wellcome Found Therapeutic heterocyclic compounds
AU694226B2 (en) * 1994-05-19 1998-07-16 Merck Sharp & Dohme Limited Piperazine, piperidine and tetrahydropyridine derivatives ofindol-3-ylalkyl as 5-HT1D-alpha agonists
ATE203533T1 (de) * 1994-06-01 2001-08-15 Astrazeneca Ab INDOLDERIVATE ALS PRODRUGS VON ß5-HT1-LIKEß REZEPTOR AGONISTEN
EP0773942A1 (en) * 1994-07-26 1997-05-21 Pfizer Inc. 4-indole derivatives as serotonin agonists and antagonists
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
GB9423682D0 (en) * 1994-11-23 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
CA2207201A1 (en) * 1994-12-06 1996-06-13 Caroline Henry Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists
DE4443892A1 (de) * 1994-12-09 1996-06-13 Bayer Ag 4-(Chinolin-2-yl-methoxy)-phenyl-essigsäurederivate
GB9501865D0 (en) * 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
WO1996029075A1 (en) * 1995-03-20 1996-09-26 Eli Lilly And Company 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
GB9515060D0 (en) * 1995-07-22 1995-09-20 Wellcome Found Therapeutic heterocyclic compounds
GB9515305D0 (en) * 1995-07-26 1995-09-20 Wellcome Found Therapeutic heterocyclic compounds
GB9516143D0 (en) * 1995-08-07 1995-10-04 Wellcome Found Improved chemical synthesis
GB9516145D0 (en) * 1995-08-07 1995-10-04 Wellcome Found Improved chemical synthesis
US6909005B1 (en) * 1995-08-07 2005-06-21 Astrazeneca Uk Limited One post synthesis of 2-oxazolidinone derivatives
AU7261196A (en) * 1995-10-10 1997-04-30 Eli Lilly And Company N-{2-substituted-3-(2-aminoethyl)-1h-indol-5-yl}-amides: new 5-ht1f agonists
US5998415A (en) * 1995-11-02 1999-12-07 Merck Sharp & Dohme Ltd. Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation, and their use of as selective agonists of 5-HT1 -like receptors
GB9609374D0 (en) * 1996-05-03 1996-07-10 Merck Sharp & Dohme Therapeutic agents
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
WO2000000490A2 (en) * 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6346625B1 (en) * 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
GB9928578D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
ES2292636T3 (es) * 2000-11-29 2008-03-16 Eli Lilly And Company 1-(2-m-metanosulfanomidofeniletil)-4-(m-trifluorometilfenil)piper.
US7458374B2 (en) * 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
EP1435945B1 (en) * 2001-06-05 2008-08-13 Aung-din, Ronald Topical migraine therapy
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
EP1490090A4 (en) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS
NZ537772A (en) 2002-06-21 2007-05-31 Suven Life Sciences Ltd Arylalkyl indoles having sertonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
DE60317333T2 (de) 2002-06-21 2008-08-28 Suven Life Sciences Ltd. Tetracyklische arylsulfonylindole mit affinität zum serotonin rezeptor
ES2204302B2 (es) * 2002-08-07 2005-03-01 Laboratorios Vita, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo.
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) * 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
JP4559230B2 (ja) 2002-11-28 2010-10-06 スベン ライフ サイエンシズ リミティド セロトニン受容体に対する親和性を有する新規n−アリールスルホニル−3−置換されたインドール、その調製方法、それを含有する医薬組成物
EA009193B1 (ru) 2002-11-28 2007-12-28 Сувен Лайф Сайенсиз Лимитед N-арилсульфонил-3-аминоалкоксииндолы
JP4571507B2 (ja) 2002-12-18 2010-10-27 スベン ライフ サイエンシズ リミティド セロトニン受容体親和性を有する四環系3−置換インドール
JP4897221B2 (ja) 2002-12-20 2012-03-14 チバ ホールディング インコーポレーテッド アミン類の合成及びその合成のための中間体
WO2004063175A1 (en) * 2003-01-13 2004-07-29 Natco Pharma Limited A novel and an improved process for the preparation of (s)-4-(4-aminobenzyl)-2- oxazolidinone
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
US20040192958A1 (en) * 2003-03-25 2004-09-30 Hyatt John Anthony Process for preparing derivatives of 4-halobutyraldehyde
US20050079166A1 (en) 2003-05-21 2005-04-14 Alexza Molecular Delivery Corporation Self-contained heating unit and drug-supply unit employing same
TWI287010B (en) * 2003-06-12 2007-09-21 Euro Celtique Sa Therapeutic agents useful for treating pain
EP1644004A4 (en) 2003-06-20 2010-10-06 Ronald Aung-Din LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS
PT1648878E (pt) * 2003-07-24 2009-07-23 Euro Celtique Sa Compostos de piperidina e composições farmacêuticas que os contêm
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
WO2005075467A2 (en) * 2004-02-06 2005-08-18 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
US7540286B2 (en) * 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
CA2576961A1 (en) * 2004-08-12 2006-03-02 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
WO2006055964A2 (en) * 2004-11-19 2006-05-26 Teva Pharmaceutical Industries Ltd. Zolmitriptan crystal forms
ATE489138T1 (de) 2005-04-13 2010-12-15 Neuraxon Inc Substituierte indolverbindungen mit nos-hemmender aktivität
EP1981860B1 (en) 2006-01-19 2011-05-25 Matrix Laboratories Ltd Conversion of aromatic diazonium salt to aryl hydrazine
US7989447B2 (en) * 2006-04-13 2011-08-02 Neuraxon, Inc. 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity
WO2008018090A2 (en) * 2006-08-09 2008-02-14 Matrix Laboratories Ltd An improved process for the preparation of zolmitriptan
CA2666149A1 (en) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
DK2425820T3 (en) 2007-02-11 2015-07-13 Map Pharmaceuticals Inc A method for the therapeutic administration of DHE in order to enable quick relief of migraine, while minimizing the adverse event profile
CZ2007158A3 (cs) * 2007-02-26 2008-10-22 Zentiva, A. S. Zpusob prípravy zolmitriptanu
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
PE20090422A1 (es) 2007-04-27 2009-04-18 Purdue Pharma Lp Derivados de piperidina, piperazina o tetrahidropiridilo como antagonistas de trpv1
JP5372913B2 (ja) * 2007-04-27 2013-12-18 パーデュー、ファーマ、リミテッド、パートナーシップ 疼痛治療に有効な治療薬
EP2201003A1 (en) * 2007-10-03 2010-06-30 Generics Ýuk¨Limited Process for the preparation of zolmitriptan, salts and solvates thereof
EP2220074A4 (en) * 2007-11-16 2012-01-04 Neuraxon Inc 3,5-SUBSTITUTED INDOL COMPOUNDS WITH NOS AND NOREPINEPHRINE RECOVERY-HEMDERING EFFECT
MX356032B (es) * 2007-11-16 2018-04-11 Neuraxon Inc Compuestos indola y métodos para tratar el dolor visceral.
AU2008321353A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
CN101181267B (zh) * 2007-11-30 2010-09-08 重庆医科大学医药研究所 佐米曲普坦舌下片
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
JP2011526889A (ja) 2008-06-30 2011-10-20 アフギン ファーマ,エルエルシー 局所局部的神経作用療法
US20100217013A1 (en) * 2008-12-15 2010-08-26 Wenge Li Enantioselective process for the preparation of zolmitriptan
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
US20110038928A1 (en) * 2009-08-12 2011-02-17 Glenmark Generics Ltd Orally disintegrating tablets of zolmitriptan
US9186359B2 (en) 2010-10-15 2015-11-17 Contera Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
PE20141531A1 (es) 2011-06-22 2014-10-23 Purdue Pharma Lp Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos
PL2734634T3 (pl) 2011-07-22 2020-03-31 The University Of Chicago Igf-1 do zastosowania do leczenia migreny
US9006453B2 (en) 2011-09-02 2015-04-14 Emcure Pharmaceuticals Limited Process for preparation of zolmitriptan
CA2870123C (en) 2012-04-18 2021-02-23 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
CA2895816C (en) 2012-12-21 2021-02-23 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
AU2016226267A1 (en) 2015-03-02 2017-09-28 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
US20210069122A1 (en) 2016-01-27 2021-03-11 Instar Technologies A.S. Oromucosal nanofiber carriers for therapeutic treatment
CA3030089C (en) 2016-07-11 2024-04-23 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
AU2020292994A1 (en) 2019-06-14 2022-01-06 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB148879A (en) * 1919-02-14 1921-11-10 Emil Vincance Noser Locks for shift levers of automobiles
US3320282A (en) * 1962-10-29 1967-05-16 Pfizer & Co C Process for preparing esters of 2-hydroxy-3-(3-indolyl) alkanoic acids
US3879410A (en) * 1971-02-08 1975-04-22 Messrs Lab Guidotti & C S P A 4-Aryl-4-oxazolin-2-ones exhibiting myotonic and myorelaxing activity
BE795457A (fr) * 1972-02-16 1973-08-16 Clin Midy Amines indoliques, leur preparation et leur application en therapeutiques
FR2179582B1 (no) * 1972-04-13 1975-10-10 Synthelabo
US3873559A (en) * 1973-03-30 1975-03-25 Squibb & Sons Inc Heterocyclic carboxamido thiazolinyl indoles
US4042595A (en) * 1973-08-01 1977-08-16 Snam Progetti S.P.A. Processes for the production of heterocyclic compounds
IT995110B (it) * 1973-08-01 1975-11-10 Snam Progetti Procedimento per la produzione di composti eterociclici e prodotti ottenuti
US3931229A (en) * 1973-08-23 1976-01-06 Warner-Lambert Company 3-Thiomethyl-2[2-(dialkylamino)ethyl]indoles
US4049816A (en) * 1975-03-24 1977-09-20 Beecham Group Limited Antiviral 2-amino-5-[1-(indol-3-yl)alkyl]-2-thiazolin-4-ones
FR2315925A1 (fr) * 1975-07-04 1977-01-28 Nippon Chemiphar Co Nouveaux derives de 5-benzyle-2-oxazolidone, leur procede de preparation et leur application en therapeutique
GB1482879A (en) * 1975-07-24 1977-08-17 Nippon Chemiphar Co 5-benzyl-2-oxazolidone derivatives and a process for producing the same
GB1469200A (en) * 1975-11-28 1977-03-30 Warner Lambert Co 3-thiomethyl-2-2-dialkylamino-ethyl-indoles
DE2557341A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
IT1109002B (it) * 1977-09-22 1985-12-16 Menarini Sas Derivati del 2 oxazolidone e loro metodi di preparazione
US4198501A (en) * 1977-12-20 1980-04-15 Hoffmann-La Roche Inc. Synthesis of tryptophans
US4137404A (en) * 1977-12-20 1979-01-30 Hoffmann-La Roche Inc. Synthesis of tryptophans
JPS6014032B2 (ja) * 1978-01-20 1985-04-11 日本ケミフア株式会社東京 5‐フエネチル‐2‐オキサゾリドン誘導体およびその製法
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
DE2933636A1 (de) * 1978-08-30 1980-03-20 Sandoz Ag Neue n-phenylindolinderivate, ihre herstellung und pharmazeutische praeparate, welche diese verbindungen enthalten
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
US4255432A (en) * 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
US4272555A (en) * 1979-09-21 1981-06-09 Monsanto Company Conversion of carbon-containing materials to carbon monoxide
EP0083566A1 (en) * 1980-04-10 1983-07-13 Sandoz Ag Isoxazolyl indoles
JPS574986A (en) * 1980-06-13 1982-01-11 Paamakemu Asia:Kk Preparation of oxazolidine derivative
US4367234A (en) * 1980-07-28 1983-01-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4753956A (en) * 1981-01-02 1988-06-28 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
ES504693A0 (es) * 1980-08-12 1982-12-01 Glaxo Group Ltd Un procedimiento para la preparacion de un derivado del indol.
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
US4407811A (en) * 1981-01-02 1983-10-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4448971A (en) * 1981-01-02 1984-05-15 Pfizer Inc. Hypoglycemic 5-phenyl-substituted oxazolidine-2,4-diones
US4399296A (en) * 1981-01-02 1983-08-16 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
JPS57169458A (en) * 1981-04-13 1982-10-19 Paamakemu Asia:Kk Preparation of indole derivative
CH656124A5 (de) * 1982-04-13 1986-06-13 Sandoz Ag 2-substituierte-3-indolamine, verfahren zu deren herstellung sowie deren verwendung.
IT1170387B (it) * 1982-06-07 1987-06-03 Glaxo Group Ltd Composti eterociclici, procedimento per prepararli e composizioni farmaceutiche che li contengono
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
US4500717A (en) * 1983-03-28 1985-02-19 The Dow Chemical Company Process for preparation of 2-oxazolidinones
US4831153A (en) * 1983-06-27 1989-05-16 The Dow Chemical Company Preparation of N-vinyl-2-oxazolidinone
GB8321813D0 (en) * 1983-08-12 1983-09-14 Vickers Plc Radiation sensitive compounds
DE3333450A1 (de) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt Trihalogenmethylgruppen enthaltende carbonylmethylenheterocyclen, verfahren zu ihrer herstellung und lichtempfindliches gemisch, das diese verbindungen enthaelt
HU196752B (en) * 1983-12-06 1989-01-30 Glaxo Group Ltd Process for production of medical compositions containing indole-derivatives and these compounds
DE3430284A1 (de) * 1984-08-17 1986-02-27 Troponwerke GmbH & Co KG, 5000 Köln Neue tryptamin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung
GB2168973B (en) * 1984-12-04 1988-02-03 Glaxo Group Ltd Indole derivatives
GB8431426D0 (en) * 1984-12-13 1985-01-23 Glaxo Group Ltd Chemical compounds
DE3514696A1 (de) * 1985-04-24 1986-11-06 Bayer Ag, 5090 Leverkusen N-indolylethyl-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung
DE3531658A1 (de) * 1985-09-05 1987-03-12 Boehringer Mannheim Gmbh Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel
EP0225726B1 (en) * 1985-11-08 1991-04-17 Glaxo Group Limited Indole derivatives
GB8531612D0 (en) * 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
SE451840B (sv) * 1986-01-03 1987-11-02 Astra Laekemedel Ab Optiskt rent monohydrat av s-(-)-1-propyl-2',6'-pipekoloxylididhydroklorid, sett att framstella denna och farmaceutiska beredningar for lokalbedovning
GB8600398D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8607824D0 (en) * 1986-03-27 1986-04-30 Glaxo Group Ltd Chemical compounds
DE3643957A1 (de) * 1986-12-22 1988-06-30 Bayer Ag Substituierte n-methylisoxazolidine
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
EP0303507B1 (en) * 1987-08-13 1993-07-28 Glaxo Group Limited Indole derivatives
DE3730777A1 (de) * 1987-09-12 1989-03-23 Basf Ag Verfahren zur herstellung von imidazolidinonen und oxazolidinonen
US4965268A (en) * 1987-10-09 1990-10-23 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4801600A (en) * 1987-10-09 1989-01-31 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4921869A (en) * 1987-10-09 1990-05-01 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
DE3823299A1 (de) * 1988-07-07 1990-01-11 Schering Ag Substituierte phenyl-pyrrolidin-2-one, -oxazolidin-2-one und -imidazolidin-2-one, ihre herstellung sowie verwendung in arzneimitteln
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
DE68929303T2 (de) * 1988-09-15 2002-05-02 Upjohn Co 3-(Stickstoff substituierte)phenyl-5-beta-amidomethyloxazoliden-2-one
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
DE3939238A1 (de) * 1989-11-28 1991-05-29 Bayer Ag Heterocyclisch substituierte acrylsaeureester
DE4013907A1 (de) * 1990-04-26 1991-10-31 Schering Ag Verfahren zur herstellung von gramin-derivaten
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
GB9104136D0 (en) * 1991-02-27 1991-04-17 Merck Sharp & Dohme Therapeutic agents
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives

Also Published As

Publication number Publication date
RU2160736C2 (ru) 2000-12-20
NO920494D0 (no) 1992-02-06
EP0636623A1 (en) 1995-02-01
EP0636623B1 (en) 2001-08-16
UA37178C2 (uk) 2001-05-15
DE69127260D1 (de) 1997-09-18
FI105686B (fi) 2000-09-29
EP0486666B1 (en) 1997-08-13
HU211479A9 (en) 1995-11-28
FI960155A0 (fi) 1996-01-12
WO1991018897A1 (en) 1991-12-12
MC2210A1 (fr) 1992-11-26
HU219974B (hu) 2001-10-28
US5466699A (en) 1995-11-14
PT97888A (pt) 1992-05-29
AU646871B2 (en) 1994-03-10
IE20010862A1 (en) 2003-03-05
LV10274B (en) 1995-04-20
IL98392A (en) 1996-01-19
US5399574A (en) 1995-03-21
IL114690A0 (en) 1995-11-27
IL114690A (en) 1997-02-18
JP2738461B2 (ja) 1998-04-08
SI9111010B (sl) 2005-02-28
SI21560A (sl) 2005-02-28
DK0486666T3 (da) 1998-03-30
EG19650A (en) 1995-09-30
DE19775091I2 (de) 2007-05-24
AU7957091A (en) 1991-12-31
KR100215627B1 (ko) 1999-08-16
NO1998005I1 (no) 1998-01-21
CA2282890C (en) 2001-07-31
DE69132691T2 (de) 2002-06-20
FI106262B (fi) 2000-12-29
LV10274A (lv) 1994-10-20
NZ238424A (en) 1993-12-23
IE911931A1 (en) 1991-12-18
CA2064815C (en) 1999-11-16
CS172791A3 (en) 1992-02-19
PT97888B (pt) 1998-12-31
YU101091A (sh) 1994-04-05
NL980001I2 (nl) 1998-05-06
FI920503A0 (fi) 1992-02-06
GR3024828T3 (en) 1998-01-30
PL166214B1 (pl) 1995-04-28
LU90205I2 (fr) 1998-04-06
SK281621B6 (sk) 2001-05-10
FI20001406A (fi) 2000-06-13
HU9200384D0 (en) 1992-06-29
LT3264B (en) 1995-05-25
NL980001I1 (nl) 1998-03-02
LTIP419A (en) 1994-11-25
HK1000534A1 (en) 1998-04-03
DE69127260T2 (de) 1997-12-04
ATE204275T1 (de) 2001-09-15
US5863935A (en) 1999-01-26
SI9111010A (en) 1997-12-31
YU48855B (sh) 2002-06-19
NO300634B1 (no) 1997-06-30
IL98392A0 (en) 1992-07-15
SA05260104B1 (ar) 2006-04-04
KR920702359A (ko) 1992-09-03
JPH05502679A (ja) 1993-05-13
HUT62289A (en) 1993-04-28
MX9203421A (es) 1992-07-01
HRP940524A2 (en) 1996-06-30
SA05260104A (ar) 2005-12-03
CA2282890A1 (en) 1991-12-08
ATE156823T1 (de) 1997-08-15
CZ288351B6 (en) 2001-05-16
MY110226A (en) 1998-03-31
ES2104708T3 (es) 1997-10-16
CA2064815A1 (en) 1991-12-08
SI21560B (sl) 2005-04-30
HRP940524B1 (en) 1998-10-31
EP0486666A1 (en) 1992-05-27
FI960155A (fi) 1996-01-12
DE69132691D1 (de) 2001-09-20

Similar Documents

Publication Publication Date Title
NO920494L (no) Terapeutiske, heterosykliske forbindelser
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
ES8401032A1 (es) Procedimiento para la obtencion de 1,4-dihidropiridinas.
FI102069B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten indolijohdannaisten valmistamiseksi
BG98124A (en) Active pyrrole-(2,3-)pyridine derivatives
YU46937B (sh) Derivati kondenzovanog pirazol-3-okso-propannitrila i postupak za njihovo dobijanje
DE69311118D1 (de) Phosphono-arylethanolamin-verbindungen mit antihyperglykämischer und/oder antiobeser wirkung
GB1424450A (en) Isoindoline intermediates
ES2012736A6 (es) Procedimiento para la preparacion de derivados triciclicos de 3-oxopropanonitrilo.
DE69106008D1 (de) Behandlung von Schlaf-Apnoea mit Azapironderivaten.
ATE123025T1 (de) 2-amino-n-(((4-(aminocarbonyl)pyrimidin-2- yl&gt;amino&gt;alkyl&gt;-pyrimidin-4- carbonsäureamidderivate, ihre herstellung und ihre anwendung in der therapeutica.
BG95629A (en) Derivatives of 10, 11, 12, 13 - tetrahytdrodesmicozine, method for preparing them, and their use as pharmaceutical preparations
ATE44741T1 (de) 2-(n-substituierte guanidino)-4heteroarylthiazole als mittel gegen geschwuere.

Legal Events

Date Code Title Description
MK1K Patent expired
MK1K Patent expired